- Investors & Media
- Investors & Media
- Contact Us
The Company's exports in the first nine months of 2012 grew to $27.5 million
Kamada received the award from the President of Israel
The award was given based on the success of the Company's strategy in selling GLASSIA in the U.S. and worldwide, transforming it to an export-oriented company
Ness Ziona, Israel, January 7, 2013. Kamada Ltd. (TASE: KMDA), an Israeli biopharmaceutical company, specializing in development, manufacturing and marketing of specialty plasma bio-therapeutics by intravenous or inhaled methods of administration for life saving uses, reports receiving the title of Outstanding Exporter in 2011 from the Foreign Trade Administration, part of the Israeli Ministry of Industry, Trade and Labor.
David Tzur, Kamada's CEO, receive the title from the President of Israel, Mr. Shimon Peres
Kamada received the Award of Outstanding Performance based on its notable growth in exports, as part of the Company's successful strategy to sell GLASSIA, the intravenous AAT product for the treatment of AAT deficiency, internationally. GLASSIA is currently marketed in the U.S., as part of its strategic cooperation with Baxter, and in other countries worldwide.
The Company's exports in 2011 crossed the $30 million threshold and for the first time surpassed domestic sales in Israel. In the first nine months of 2012, exports continued to grow and reached approximately $27.5 million, a growth of 25% compared to exports during the same period in 2011. Kamada's sales forecast for 2012 is approximately $72 million, compared to sales of approximately $59 million in 2011.
Certificates and awards for outstanding performance were presented to Kamada's CEO, Mr. David Tsur, and to senior company executives by the President of Israel, Mr. Shimon Peres, and members of the awards committee, at a ceremony held today at the Presidential Residence in Jerusalem.
Kamada's employees, after the ceremony at the Presidential Residence
Kamada has a cutting-edge patent-protected technology for the manufacture of approximately ten drugs marketed in more than fifteen countries worldwide. The company's products have been sold for many years with cumulative sales of more than $200 million. In 2010 Kamada received U.S. FDA approval for marketing in the U.S. of its flagship product (GLASSIA), an AAT protein product for the treatment of genetic AAT deficiency, and became the first Israeli company to receive the U.S. FDA approval to market a biological product. Kamada's AAT protein is an Israeli development and the first liquid ready to use, injectable product approved in the world.
Kamada is a world leader in the development of the "next generation" AAT product delivered by inhalation, and is currently at an advanced clinical stage towards registering the product and marketing it to a larger number of patients worldwide, subject to the success of the trial. Kamada announced earlier this year its success in a unique phase I/II clinical trial for treating Type-1 Diabetes with its AAT product, demonstrating high safety and preliminary efficacy results.
The Company's vision is to develop, produce and offer patients unique, high quality biopharmaceutical products that will improve their quality of life and help to save lives. Kamada has over time strengthened its presence in the world's pharmaceutical market with in-house capabilities, know-how, technology and human capital to be positioned as an innovative, pioneering firm. This is evidenced by the Company's ability to secure partnership agreements with major pharmaceutical companies such as Baxter, Chiesi, Pari and Kedrion.
On December 15, 2012, Kamada joined the prestigious TA-100 Index, which includes 100 largest companies (by market value) on the Tel Aviv Stock Exchange.
David Tsur, CEO of Kamada, today stated: "We are pleased and grateful at being awarded the title of Outstanding Exporter, reflecting the longstanding business success of the company and its adherence to growth targets in all the export markets in which it operates. This award is the result of hard, dedicated professional work on the part of all the company's employees and managers, and I am proud of the human resources which exist in Kamada. The award supplements a long list of achievements gained and prizes won by the company in the past year, indicating the continuing international and local recognition of the company's breakthrough technology and its ability to transform vision into reality and business success. Kamada has been chosen this year to be among Deloitte's 500 fastest growing companies in Europe, the Middle East and Africa, while it has also been awarded a national prize for quality and excellence.”
Kamada specializes in the development, manufacture, and marketing of specialty intravenous, injectable, or inhaled life-saving therapeutics. The company manufactures about ten drugs marketed in fifteen countries worldwide, and employs cutting-edge patented technology for protein purification and separation. Kamada has a line of unique products, including some in the advanced stages of clinical trials. Following the development of GLASSIA, which has FDA approval and is exclusively marketed in the US by Baxter, Kamada is developing its “next generation” product, which is currently in Phase II/III of a clinical trial: AAT administered by inhalation, for the treatment of Alpha-1 Antitrypsin deficiency, also known as hereditary emphysema. Kamada also succesfully completed Phase I/II of a clinical trial of intravenous AAT for treatment of Diabetes type-1, and is preparing for Phase II/III of a clinical trial in the US of an anti-rabies drug as part of its collaboration with the pharmaceutical company Kedrion SpA.
This announcement includes “prospective information”, as defined in The Securities Law 1968, whose materialization is dependent upon various factors, such as completing the recruitment of patients for clinical trials, the results thereof, and receiving the various regulatory approvals required to market the products.
Further information is available on the Kamada website: www.kamada.com
For more information:
Gil Efron, CFO